Location: Smithfield, RI
The Process Controls Engineer is responsible for configuration, operation, and maintenance of the plant’s process control and data historian systems.
Work with other members of the Automation group to configure and maintain the process control and historian systems.
Troubleshoot problems with the process control and historian systems.
Assist Validation in the preparation and execution of validation protocols.
Assist in maintaining design documentation to assure they reflect the operational parameters of the process control systems.
Provide off-hours coverage (nights and weekends), as necessary, to assure process control systems are able to support manufacturing operations.
Previous work in a pharmaceutical or biotechnology facility where cGMP practices are followed is preferred.
Ideally will have a minimum of two to five years’ experience working with control systems.
B.S. or M.S Degree in Engineering or Computer Science
Experienced in PLC programming in ladder logic, sequential function, structured text, or scripts.
Experience maintaining controls and communications networks.
Understanding of equipment used in the manufacturing of pharmaceuticals is desired.
Experience with Rockwell Automation FactoryTalk Historian or OSIsoft PI data historian is desired.
Experience with batch control software and an understanding of S88 batch methodology is desired.
Good interpersonal skills are required, as is the ability to communicate well, both verbally and written documents.
The individual in this position is expected to represent Alexion Pharmaceutical interests, objectives and policies in a professional and responsible manner.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris ® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 35 countries for the treatment of PNH, and in the United States for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com .
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic...